Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Core Viewpoint - Xilio Therapeutics, Inc. will implement a 1-for-14 reverse stock split to increase the per-share market price of its common stock and regain compliance with Nasdaq listing requirements [2][4]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 p.m. Eastern Time on March 13, 2026, and trading on a split-adjusted basis will begin on March 16, 2026 [1][3]. - The number of outstanding shares will decrease from approximately 73.5 million to about 5.2 million shares [4]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment instead [5]. Group 2: Stockholder and Market Impact - The reverse stock split was approved by stockholders at a Special Meeting on February 23, 2026, with the final ratio determined by the Board of Directors [2]. - The split aims to help the company meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market [2]. - All outstanding warrants and securities will be adjusted accordingly, and proportionate adjustments will be made to equity incentive plans [4][6]. Group 3: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing masked immuno-oncology therapies to improve cancer treatment outcomes while minimizing systemic side effects [7].